Unprecedented drug design minimising side effects
HRI has developed an unprecedented drug design strategy that tailors drugs with fatty acids to minimise side effects.
Global media interest in HRI’s breakthrough anti-clotting drug for COVID-19
The revolutionary new anti-clotting medicine developed by HRI has attracted global media interest due to its far-reaching impact.
HRI researchers on cusp of worldwide breakthrough in COVID-19 treatment
Researchers at HRI believe they may hold the key to controlling the deadly blood clots caused by COVID-19.
Key to helping critically ill COVID-19 patients sits with Sydney-based researchers’ blockbuster anti-clotting drug
HRI is on the precipice of a significant research breakthrough for the treatment of one of the major life-threatening complications of the novel coronavirus (COVID-19), microscopic blood clots.
Dr Lining (Arnold) Ju – Young Tall Poppy Science Award
HRI’s Dr Lining (Arnold) Ju has been recognised for his research excellence and public outreach in the Young Tall Poppy Science Awards for his research into heart disease.
Dr Mary Kavurma awarded ACvA Research Catalyst Grant
Dr Mary Kavurma has been awarded an Australian Cardiovascular Alliance Research Catalyst Grant for her research into peripheral artery disease.
Why our hearts fail: research
Scientists at HRI and The University of Sydney have made new heart failure discoveries in an innovative world-first project examining cryo-preserved human hearts.
Cardiovascular Medical Devices Group reviews next-generation surfaces
HRI's Cardiovascular Medical Devices Group reviews next-generation liquid-infused surfaces that could be used to improve medical devices like heart bypass machines.
HRI undertakes critical research into COVID-19-related heart disease
The Heart Research Institute, in partnership with major NSW hospitals, universities, and other research institutions, is striving to unravel the deadly link between the coronavirus (COVID-19) and cardiovascular disease.